{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:18:05Z","timestamp":1783948685405,"version":"3.55.0"},"reference-count":43,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s273660","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T18:30:06Z","timestamp":1643049006000},"page":"297-304","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Camilla","family":"Muccini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Canetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9656-7217","authenticated-orcid":true,"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"key":"ref2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. Accessed October 28, 2021."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"ofaa456","DOI":"10.1093\/ofid\/ofaa456","volume":"7","author":"Galli","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"ref4","unstructured":"Hsu R, Fusco J, Henegar C, et al. Clinical outcomes of heavily treatment experienced individuals in the OPERA cohort. AIDS 2020: 23rd International AIDS Conference Virtual; July 6\u201310; 2020; Abstract PEB0234."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/nchembio.2460","volume":"13","author":"Pancera","year":"2017","journal-title":"Nat Chem Biol"},{"key":"ref6","unstructured":"US Food and Drug Administration. FDA approves new HIV treatment for patients with limited treatment options; 2020. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approvesnew-hiv-treatment-patients-limitedtreatment-options. Accessed December 9, 2021."},{"key":"ref7","unstructured":"European medicines agency. EMA\/CHMP\/613669\/2020. Rukobia (fostemsavir); 2020."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","volume":"61","author":"Meanwell","year":"2018","journal-title":"J Med Chem"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/COH.0000000000000469","volume":"13","author":"Cahn","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1128\/AAC.00759-10","volume":"55","author":"Hanna","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","unstructured":"Wang T, Ueda Y, Connolly TP, et al. Use of a phosphonoxymethyl prodrug approach to successfully improve the oral delivery of HIV-1 attachment inhibitors: design, preclinical profile, and human exposure [abstract MEDI-346]. Presented at: 239th American Chemical Society National Meeting; 21\u201325 March; 2010; San Francisco, CA."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1093\/infdis\/jis432","volume":"206","author":"Nettles","year":"2012","journal-title":"J Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"11013","DOI":"10.1073\/pnas.1832214100","volume":"100","author":"Lin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1021\/jm201218m","volume":"55","author":"Kadow","year":"2012","journal-title":"J Med Chem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bmcl.2015.11.009","volume":"26","author":"Swidorski","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/jps.23476","volume":"102","author":"Brown","year":"2013","journal-title":"J Pharm Sci"},{"key":"ref17","unstructured":"Food and Drug Administration: RUKOBIA (fostemsavir) extended-release tablets, for oral use. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212950s000lbl.pdf. Accessed on January 20, 2022."},{"key":"ref18","unstructured":"Sevinsky H, Magee M, Ackerman P, et al. The effect of food on the pharmacokinetics of the HIV-1 attachment inhibitor temsavir, the active moiety of the prodrug fostemsavir. Abstract (P_23) presented at: 18th International Workshop on Clinical Pharmacology of Antiviral Therapy; June 14\u201316; 2017; Chicago, IL."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"S867","DOI":"10.1093\/ofid\/ofz360.2178","volume":"6","author":"Moore","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"S430","DOI":"10.1093\/ofid\/ofx163.1086","volume":"4","author":"Sevinsky","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/1060028020962424","volume":"55","author":"Hiryak","year":"2021","journal-title":"Ann Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1128\/AAC.00426-12","volume":"56","author":"Nowicka-Sans","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/jac\/dkt412","volume":"69","author":"Zhou","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1093\/jac\/dkaa073","volume":"75","author":"Bouba","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/jac\/dkaa034","volume":"75","author":"Lepore","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/jac\/dky271","volume":"73","author":"Alessandri-Gradt","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0b013e3181c990bf","volume":"53","author":"Molina","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01173-10","volume":"55","author":"Zhou","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jac\/dkaa474","volume":"76","author":"Gartland","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1128\/AAC.00513-13","volume":"57","author":"Li","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/cts.12763","volume":"13","author":"Lagishetty","year":"2020","journal-title":"Clin Transl Sci"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1016\/S2352-3018(15)00177-0","volume":"2","author":"Lalezari","year":"2015","journal-title":"Lancet HIV"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"Kozal","year":"2020","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","volume":"7","author":"Lataillade","year":"2020","journal-title":"Lancet HIV"},{"key":"ref35","unstructured":"Rukobia. Package insert. ViiV healthcare; 2020."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/QAD.0000000000002851","volume":"35","author":"Ackerman","year":"2021","journal-title":"AIDS"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40271-021-00534-y","volume":"15","author":"Anderson","year":"2021","journal-title":"Patient"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003097","author":"Ronald","year":"2021","journal-title":"AIDS"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1093\/jac\/dkaa178","volume":"75","author":"Saladini","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"ref40","unstructured":"Food and Drug Administration. Ibalizumab-UIYK. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=761065. Accessed October 28, 2021."},{"key":"ref41","first-page":"75","volume":"24","author":"Molina","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"ref42","first-page":"77","volume":"24","author":"Molina","year":"2020","journal-title":"Ethnicity"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1038\/s41467-020-17753-w","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=77835","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=77835","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T18:30:14Z","timestamp":1643049014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/efficacy-and-safety-profile-of-fostemsavir-for-the-treatment-of-people-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":43,"URL":"https:\/\/doi.org\/10.2147\/dddt.s273660","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}